NASDAQ: VCELVericel Corp Stock
$41.23+0.41 (+1%)
Updated Apr 17, 2025
VCEL Price
$41.23
Fair Value Price
$10.99
Market Cap
$2.06B
52 Week Low
$37.76
52 Week High
$63.00
P/E
196.33x
P/B
7.06x
P/S
11.31x
PEG
2.48x
Dividend Yield
N/A
Revenue
$237.22M
Earnings
$10.36M
Gross Margin
72.6%
Operating Margin
4.69%
Profit Margin
4.4%
Debt to Equity
0.48
Operating Cash Flow
$58M
Beta
1.44
Next Earnings
May 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A
VCEL Overview
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine VCEL's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
VCEL
Ranked#43 of 463
Ranked#43 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important VCEL news, forecast changes, insider trades & much more!
VCEL News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how VCEL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VCEL ($41.23) is overvalued by 275.28% relative to our estimate of its Fair Value price of $10.99 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
VCEL ($41.23) is not significantly undervalued (275.28%) relative to our estimate of its Fair Value price of $10.99 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
VCEL ($41.23) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VCEL due diligence checks available for Premium users.
Valuation
VCEL fair value
Fair Value of VCEL stock based on Discounted Cash Flow (DCF)
Price
$41.23
Fair Value
$10.99
Overvalued by
275.28%
VCEL ($41.23) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VCEL ($41.23) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VCEL ($41.23) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
VCEL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
196.33x
Industry
-177.72x
Market
27.98x
VCEL is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
VCEL is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
VCEL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
7.06x
Industry
4.05x
VCEL is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
VCEL price to earnings growth (PEG)
For valuing profitable companies with growth potential
VCEL is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
VCEL's financial health
Profit margin
Revenue
$75.4M
Net Income
$19.8M
Profit Margin
26.3%
VCEL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
VCEL's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$432.7M
Liabilities
$140.8M
Debt to equity
0.48
VCEL's short-term assets ($212.78M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VCEL's short-term assets ($212.78M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VCEL's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
VCEL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$22.2M
Investing
-$14.7M
Financing
$7.1M
VCEL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VCEL vs Biotech Stocks
Vericel Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.